Clinical Trials Logo

Clinical Trial Summary

Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).

With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.

The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03096405
Study type Observational
Source Groupe Hospitalier Paris Saint Joseph
Contact
Status Completed
Phase N/A
Start date February 1, 2014
Completion date February 28, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes N/A
Terminated NCT05225558 - A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia Phase 2
No longer available NCT04597242 - Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia